
⸺ Synova Research
KLOW 160mg in a pre-mixed, pH-balanced 3ml cartridge. 6 clicks = GHK-Cu 2mg / BPC-157 0.4mg / TB-500 0.4mg / KPV 0.4mg.
Secure checkout via UK open banking. Free shipping on orders over £100.
Next-day UK dispatch
Order before midnight
Research use only
Not for human consumption
⸺ Important
⸺ Overview
KLOW Cartridge by ChemAesthetic delivers the KLOW research blend — GHK-Cu, BPC-157, TB-500 and KPV — in a stabilised, pH-balanced 3ml cartridge. Supplied pre-mixed with no reconstitution required, calibrated so 6 clicks delivers GHK-Cu 2mg, BPC-157 0.4mg, TB-500 0.4mg and KPV 0.4mg.
⸺ Mechanism of Action
GHK-Cu drives copper-dependent collagen and elastin gene expression. BPC-157 influences growth-factor and nitric-oxide signalling linked to tissue protection. TB-500 regulates actin dynamics and cell migration. KPV modulates NF-κB and inflammatory cytokine output. Together the four peptides target complementary repair, skin and inflammation pathways in preclinical models.
⸺ Research
GHK-Cu research shows enhanced collagen and elastin synthesis and improved dermal architecture in preclinical models.
Animal models with BPC-157 and TB-500 report improved tendon, ligament and muscle repair with reduced inflammation at injury sites.
Preclinical work with KPV describes reduced inflammatory markers across gut, skin and systemic models.
Summarised from preclinical literature for informational purposes only. Not medical or veterinary advice. Synova Research products are sold strictly for in-vitro and laboratory research.
⸺ Details

Investigational triple receptor agonist targeting GLP-1, GIP and glucagon — studied in animal models for appetite control, energy expenditure and glucose balance.

Dual GLP-1 and GIP receptor agonist studied in preclinical models for glucose regulation, insulin sensitivity and energy balance.

Synthetic analogue of the GLP-1 hormone used in research to study glucose regulation, insulin secretion and the incretin response.